DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Ou SH, Jänne PA, Bartlett CH et al.
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.
Ann Oncol 2014;
25: 415-422
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.